Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note published on Saturday, December 2nd.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
OSUR has been the topic of a number of other reports. Canaccord Genuity reissued a buy rating and issued a $22.00 price objective on shares of OraSure Technologies in a report on Tuesday, September 19th. ValuEngine downgraded OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Finally, Jefferies Group reiterated a buy rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. OraSure Technologies has an average rating of Buy and a consensus price target of $18.21.
Shares of OraSure Technologies (OSUR) opened at $17.40 on Friday. The stock has a market capitalization of $1,051.64, a P/E ratio of 33.35, a price-to-earnings-growth ratio of 3.33 and a beta of 1.28. OraSure Technologies has a 12 month low of $8.39 and a 12 month high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. OraSure Technologies’s revenue was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. equities analysts predict that OraSure Technologies will post 0.42 earnings per share for the current year.
In related news, Director Mara G. Aspinall purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the transaction, the chief executive officer now owns 743,058 shares in the company, valued at approximately $16,755,957.90. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Mercantile Trust Co. acquired a new position in OraSure Technologies during the 2nd quarter worth approximately $104,000. Pinebridge Investments L.P. purchased a new stake in shares of OraSure Technologies during the 2nd quarter worth approximately $131,000. Victory Capital Management Inc. boosted its stake in shares of OraSure Technologies by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,360 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $186,000. Finally, Profund Advisors LLC boosted its stake in shares of OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 293 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/13/zacks-investment-research-upgrades-orasure-technologies-osur-to-hold.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Get a free copy of the Zacks research report on OraSure Technologies (OSUR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.